Safety and Efficacy of Two Dosages of Inhaled TPI ASM8 Compared to Placebo in Mild to Moderate Asthmatic Patients

Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Groups, To Evaluate And Compare The Safety, Tolerability And Efficacy Of Two Dosages Of Inhaled TPI ASM8 Administered For 14 Days In Patients With Mild to Moderate Asthma.

This study will evaluate the efficacy, safety and tolerability of two dosages of a new drug TPI ASM8 administered by inhalation for 14 days to mild to moderate asthmatic patients, aged between 18-65, non-smokers . The study will also look at the nature and quantity of inflammatory white cells in the lung secretions and in the blood, and some additional inflammation markers.

See above

Inclusion Criteria:

• Age 18-65 y. old, non or ex-smokers for > 6 months
• Mild to moderate asthmatic in general good health
• On either low-dose inhaled corticosteroid or steroid naive
• No other asthma medication
• Regular sputum producer
• EOS more than 3% at randomization,
• FEV1 > 70%

Exclusion Criteria:

• Respiratory infection within last 4 weeks
• Any condition that may affect the conduct of the study as per the investigators